BeOne Medicines revenue and financials
$362.78Change from previous close: +0.31%Absolute change: +$1.13
In the fiscal year ended December 2025, BeOne Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8,189 | 5,921 | 5,805 | 6,379 | 8,646 | 5,601 | 1,612 | 2,250 | 1,046 | 406 |
| Current assets | 6,234 | 3,992 | 4,203 | 5,207 | 7,614 | 4,961 | 1,173 | 1,944 | 913 | 374 |
| Cash and equivalents | 4,548 | 2,627 | 3,172 | 3,870 | 4,376 | 1,382 | 618 | 713 | 240 | 87.5 |
| Short-term investments | — | — | 2.6 | 665 | 2,245 | — | — | — | — | — |
| Receivables | 887 | 709 | 396 | 199 | 500 | — | — | — | — | — |
| Inventory | 608 | 495 | 416 | 282 | 243 | — | — | — | — | — |
| Net property, plant and equipment | 1,790 | 1,718 | 1,419 | 956 | 705 | — | — | — | — | — |
| Goodwill | — | — | — | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | — |
| Other intangible assets | 62.7 | 51.1 | 57.1 | 40.6 | 46.7 | — | — | — | — | — |
| Long-term investments | 61.7 | 129 | 89.6 | 91.8 | 101 | — | — | — | — | — |
| Current liabilities | 1,829 | 2,215 | 1,810 | 1,469 | 1,600 | 1,075 | 310 | 246 | 150 | 35.1 |
| Accounts payable | 479 | 405 | 315 | 295 | 262 | — | — | — | — | — |
| Long-term debt | 836 | 1,215 | 198 | 209 | 1,288 | 184 | 580 | 40.8 | 9.2 | 17.3 |
| Total debt | 1,093 | 1,080 | 930 | 597 | — | — | — | — | — | — |
| Total liabilities | 3,827 | 2,589 | 2,268 | 1,996 | 2,403 | 1,732 | 634 | 496 | 362 | 52.9 |
| Total equity (incl. minority) | 4,361 | 3,332 | 3,537 | 4,383 | 6,133 | — | — | — | — | — |
| Retained earnings | -8,320 | -8,607 | -7,962 | -7,080 | -5,077 | — | — | — | — | — |